Key facts
- Grifols is sponsoring AlphaDetect.
- AlphaDetect is a nonprofit detection organization.
- The sponsorship aims to expand strategies for detecting Alpha-1 antitrypsin deficiency.
- Alpha-1 antitrypsin deficiency is a genetic, irreversible, and progressive condition.
Grifols has announced its sponsorship of AlphaDetect, a nonprofit organization dedicated to the detection of Alpha-1 antitrypsin deficiency. This genetic, irreversible, and progressive condition primarily affects individuals with liver and/or lung disease. The sponsorship is intended to support the expansion of proven strategies aimed at consistently identifying patients with this condition. AlphaDetect is powered and funded by Grifols, a global healthcare company.